Allan Jonathan sold $17K of STOK

Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 627 shares of Stoke Therapeutics, Inc. (STOK) at $26.33 on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Allan Jonathan
Published Oct 2, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STOK
Bearish
high confidence
Mentioned
$STOK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STOKBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Small insider sell with limited market impact.

03

What to watch

The insider retains a sizable holding, and the transaction was pre‑arranged, suggesting no urgent need to liquidate.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is a standard, pre‑arranged trade.

Company-level read

Ticker impact

$STOKBearishHigh confidence
Context

Officer Allan Jonathan sold 627 shares for $16.5K via a 10b5‑1 plan, reducing his stake to 20,598 shares.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a pre‑arranged plan, limiting impact.

Market effects

None

None

None

Counterpoint

The sale may be routine and not indicative of any negative outlook for the company.

Key entities

  • Allan Jonathan

    General Counsel & Corporate Secretary of Stoke Therapeutics

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NOCMed

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

$STOKMed

Stoke Therapeutics Q3 Earnings Call Highlights

Stoke Therapeutics (STOK) discussed Q3 earnings, highlighting plans for zorevunersen's NDA submission in 2027. The FDA supports a multicomponent endpoint for cognition/behavior. Stoke estimates 38,000 Dravet syndrome patients in key markets. STK-002 for ADOA is in Phase I trials. Q3 net loss was $73.6M, with $358.8M cash. Stoke expects funding into early 2028.

$STOKMed

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMed

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.